To the full analysis
CSPC Innovation Pharmaceutical stock: growth
300765.SZCSPC Innovation Pharmaceutical reported $322.03M in revenue for fiscal 2025, up 8.4% on the prior year, up 10.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
11.5%
per year from 2014 to 2025, per share 9.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2014 | |
|---|---|---|---|
| Revenue | 10.3% | 11.2% | 11.5% |
| Revenue per share | 6.6% | 6.3% | 9.8% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $97.58M | $16.23M | $12.79M |
| 2015 | $111.27M | $17.33M | $9.65M |
| 2016 | $133.54M | $30.98M | −$1.58M |
| 2017 | $154.64M | $29.23M | −$6.22M |
| 2018 | $185.97M | $33.57M | $15.11M |
| 2019 | $188.43M | $40.97M | $31.39M |
| 2020 | $197.56M | $44.96M | $34.69M |
| 2021 | $277.39M | $58.97M | $15.55M |
| 2022 | $393.88M | $108.92M | $78.98M |
| 2023 | $380.72M | $65.15M | $124.7M |
| 2024 | $297.04M | $8.06M | −$256.86M |
| 2025 | $322.03M | −$36.16M | −$114.58M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 2 May 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.